Abbott Laboratories $ABT Stock: Beaumont Financial Advisors LLC Decreases Holdings

Beaumont Financial Advisors LLC lessened its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 14.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 68,776 shares of the healthcare product maker's stock after selling 11,521 shares during the period. Beaumont Financial Advisors LLC's holdings in Abbott Laboratories were worth $6,797,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. increased its holdings in shares of Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after purchasing an additional 6,769,518 shares during the period. State Street Corp lifted its position in shares of Abbott Laboratories by 1.7% in the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker's stock valued at $7,343,246,000 after acquiring an additional 1,350,766 shares in the last quarter. Bank of America Corp DE acquired a new stake in Abbott Laboratories during the second quarter worth approximately $1,603,607,000. Deutsche Bank AG increased its stake in shares of Abbott Laboratories by 18.6% during the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker's stock valued at $1,515,963,000 after acquiring an additional 2,614,965 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in Abbott Laboratories in the second quarter valued at $1,082,524,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Stock Performance

ABT opened at $103.70 on Friday. The business's fifty day moving average is $105.15 and its 200-day moving average is $98.32. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $132.02. The firm has a market cap of $179.45 billion, a P/E ratio of 38.70, a price-to-earnings-growth ratio of 1.90 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting analysts' consensus estimates of $1.42. The firm had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The business's revenue for the quarter was up 14.5% on a year-over-year basis. During the same period last year, the firm posted $1.30 earnings per share. Sell-side analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories's dividend payout ratio (DPR) is 81.55%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ABT. TD Cowen cut their target price on shares of Abbott Laboratories from $135.00 to $118.00 and set a "buy" rating on the stock in a research note on Thursday. Weiss Ratings upgraded Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, September 18th. Wells Fargo & Company increased their target price on Abbott Laboratories from $112.00 to $119.00 and gave the company an "overweight" rating in a research note on Thursday. Royal Bank Of Canada cut their target price on Abbott Laboratories from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Thursday. Finally, Wolfe Research raised shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 target price on the stock in a report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, Abbott Laboratories has a consensus rating of "Moderate Buy" and a consensus target price of $118.32.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
• Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
• Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
• Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
• Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
• Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.